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ABSTRACT 
The lack of reliable biomarkers for predicting the clinical course or monitoring 
therapeutic outcome in inflammatory bowel disease is an indisputable problem. 
The aim of this study was to evaluate markers of inflammation during 
inflammatory bowel disease therapy. 
Blood chemistry markers were evaluated along with clinical activity and quality 
of life assessment during infliximab therapy in Crohn’s disease patients, both the 
immediate response (one week) and long-term effect (up to five years). A 
majority of the patients showed improvement in clinical activity and quality of 
life as well as in hemoglobin, albumin and C-reactive protein levels. Using 
Harvey-Bradshaw index and Short Health Scale, infliximab demonstrated a 
prompt effect on clinical activity and quality of life and patients showed a 
maintained responsiveness over years. 
Systemic inflammatory markers were followed along with clinical activity in 
Crohn’s disease patients undergoing the first year of infliximab therapy. Healthy 
subjects were used as controls. Clinical activity improved with each infusion. 
High-sensitive C-reactive protein, calprotectin and nitrite improved after at least 
one infusion. However, calprotectin, nitrite and soluble urokinase plasminogen 
activator receptor were elevated compared with healthy controls throughout the 
study, indicating a continuous subclinical inflammation. 
Fecal calprotectin and C-reactive protein were compared with clinical activity 
index in patients with Crohn’s disease and ulcerative colitis during infliximab 
induction therapy. Calprotectin decreased significantly in responders following 
induction therapy. Moreover, fecal calprotectin exceeding a cut-off of 221 g/g 
was associated with a flare-up during the following 24 weeks. 
Assessment of luminal NO concentrations in acute colitis patients prior to and 
after three days of corticosteroid therapy onset showed that NO levels were 
higher both at baseline and day 3 in patients responding to therapy than in non-
responders. Furthermore, NO could be used as a predictor of colectomy as study 
endpoint. Baseline NO level below 2239 ppb was significantly associated with 
colectomy within one month from onset of corticosteroid therapy. 
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1 INTRODUCTION 
1.1 INFLAMMATORY BOWEL DISEASE 
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory 
disorders in the gastrointestinal tract. Both types are characterized by periods of 
active disease (flare, relapse) with quiescent periods (remission) in between (1, 2). 
The common name for CD and UC is inflammatory bowel disease (IBD). 
General IBD symptoms are diarrhea, sometimes with blood in the stool, 
abdominal pain and weight loss, along with fever and symptoms of systemic 
inflammation in the more severe cases (3, 4). Approximately 40% of the IBD 
patients develop extraintestinal disease manifestations (5).  
CD may affect the total gastrointestinal tract from the oral cavity to the anus with 
transmural inflammation, which might lead to complications (e.g. stricturing or 
fistulizing disease) and as many as 50% of the CD patients require surgery within 
ten years from diagnosis (6, 7). The site of inflammation is often located to the 
terminal ileum, caecum or colon.  
In UC, the inflammation is restricted to the colonic mucosa, typically with 
involvement of the rectum. Depending on the anatomic extent of the 
inflammation, UC is classified as proctitis, left-sided colitis (involving the 
sigmoid colon, with or without descending colon involvement), or pancolitis. The 
inflammatory activity in CD is per definition patchy with inflamed areas 
surrounded by unaffected mucosa, whereas in UC the inflammation is 
continuous. However, differentiating Crohn colitis from UC can be difficult and 
some of the patients end up in a classification described as “indeterminate colitis” 
(8). IBD diagnosis is based on clinical symptoms and laboratory, endoscopic, 
radiological and histological findings. 
The mean age of CD diagnosis ranges from 33 to 45 years of age in a North-
American review (9), whereas the mean age for diagnosis of UC appears five to 
ten years later (10). In Europe, age peaks of incidence were reported between 15 
to 25 and 25 to 35 years of age for CD and UC, respectively (11). Chronic 
inflammation might lead to dysplasia and colorectal cancer (12, 13). The cancer 
risk depends critically on disease duration and extent of inflammation (14). The 
age of cancer diagnosis in the IBD population is much lower than for sporadic 
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colorectal cancer in the general population (13, 15). UC patients have a normal 
life expectancy whereas in CD patients it is slightly reduced (16, 17). 
The IBD incidence increases along with industrial development and westernized 
lifestyle (18, 19). The prevalence is also increasing, partly due to a decrease in 
IBD mortality (20). There seems to be a multi-factorial etiology causing IBD 
development, involving immune response deficiency, epithelial breach, triggering 
agents (microorganisms) and to some extent genetic predisposition with 
susceptible genes (e.g. nucleotide binding oligomerisation domain 2 [NOD2] in 
CD) (21-24). Heredity seems to be a stronger etiological factor in CD than in UC 
(25). Smoking is a generally accepted risk factor in CD, whereas it seems to 
reduce the risk of developing UC (6, 26, 27). 
 
1.2 IBD THERAPY 
There is as yet no curative IBD treatment, focus lies on symptomatic 
amelioration aiming to induce and maintain remission. Pharmacological therapy 
depends on disease location and activity. 
 
1.2.1 Crohn’s disease therapy 
Glucocorticosteroids (GCS) and immunomodulators represent the mainstay of 
pharmacological treatment. Sulphasalazine is effective in inducing remission in 
patients with Crohn colitis, but is limited by the sulpha-related intolerance 
occurring in some patients (28). Mild to moderate inflammation with 
involvement of terminal ileum or right colon can be treated with targeted GCS 
(budesonide). The immunosuppressor azathioprine with its metabolite 6-
mercaptopurine is given to patients with defective response to GCS. However, 
azathioprine has a slow onset of action over months and should be given as 
maintenance rather than induction therapy. Patients with signs of sepsis, bacterial 
overgrowth or perianal fistulas are treated with antibiotics when indicated. In 
severe CD or response failure, anti-tumor necrosis factor therapy (anti-TNF) is 
indicated. Surgery is an alternative to medical therapy, applied in complicated 
situations such as fibrotic strictures, fistulas, perforation or failing 
pharmacological response (29). 
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1.2.2 Ulcerative colitis therapy 
GCS or drugs based on 5-aminosalicylate (5-ASA) are indicated in mild flares 
(30). Proctitis or left-sided colitis is locally treated with suppositories or foam 
(31). Moderate flares require oral GCS, often together with increased dosing of 5-
ASA as maintenance therapy. In moderate to severe UC, combination therapy 
with GCS, 5-ASA and azathioprine is indicated. Anti-TNF is added if the 
response to combination therapy is failing (32). Severe UC entails increased risk 
for toxic dilation; those patients might need to be hospitalized and treated with 
intravenous GCS. Surgical options should be considered at the third day (or 
earlier) of intravenous GCS therapy (33). Anti-TNF can be given as rescue 
therapy. Colectomy is generally indicated in pancolitis, dysplasia or cancer, or in 
life-threatening complications such as perforation, dilation or massive bleeding 
(34).  
 
1.2.3 Biological therapy 
Infliximab (Remicade®) was the first biological agent approved for IBD therapy, 
causing a paradigm shift within the field (35, 36). Infliximab is a chimeric 
monoclonal anti-TNF antibody possessing qualities in mucosal healing, inducing 
and maintaining remission and to a certain extent also in fistula closing (37, 38). 
Through binding to and hence neutralizing soluble and receptor-bound TNF, 
infliximab blocks the TNF ability from further involvement in the inflammatory 
cascade. Colombel et al. showed that in patients with moderate to severe CD, 
who had never been exposed to immunomodulators or biological therapy, 
combination therapy with azathioprine and infliximab is superior to 
monotherapy with either choice (39). Whether anti-TNF should be introduced as 
“last-choice” therapy (step-up strategy), or first choice as a more aggressive way 
to take control over the inflammation (top-down strategy) is debated (40). 
Hitherto, step-up strategy is the common preference in the treatment of CD. In 
UC patients, the step-up strategy is a valid regimen. 
Infliximab can be given as bridging therapy to azathioprine, or as scheduled 
infusion therapy. Induction therapy is given as infusions week 0, 2 and 6 (5 
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mg/kg bodyweight) (36). Thereafter, patients receive infusions every eight weeks 
as maintenance therapy (41). 
 
1.3 CLINICAL ACTIVITY 
The Crohn’s disease activity index (CDAI) was developed as a tool to monitor 
disease activity in CD (42). It is today used as gold standard in clinical trials but 
has a few limitations. Firstly, the patient must fill in a one-week diary to correctly 
estimate the clinical activity and secondly, there is no histological or endoscopic 
criteria incorporated in the index. The validated endoscopic activity indices 
Crohn’s disease endoscopic index of severity (CDEIS) and Simple endoscopic 
score for Crohn’s disease (SES-CD), has again no definition of remission (43, 44). 
Harvey and Bradshaw developed a simplified version of the CDAI, the Harvey-
Bradshaw index (HBi), which has shown strong correlation with CDAI (45, 46) 
(Table I). HBi is based on five items and can rapidly be evaluated at clinical 
visits. Clinical response is evaluated as a decrease of t3 points in HBi, and 
clinical remission as a point of <5 (46).  
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Table I. Harvey-Bradshaw Index 
General wellbeing Very well 0 
 Slightly below par 1 
 Poor 2 
 Very poor 3 
 Terrible 4 
Abdominal pain None 0 
 Mild 1 
 Moderate 2 
 Severe 3 
Number of liquid stools per day  1 p/each 
Abdominal mass None 0 
 Dubious 1 
 Definite 2 
 Definite and tender 3 
Complications  1 p/each 
 
In the 1950’s, Truelove and Witts created a UC activity index built on a three 
graded scale of disease activity which is still in use (47). Another commonly 
employed UC index is the disease activity index (DAI), as developed by 
Sutherland et al. (48) (Table II). DAI is nearly identical to the Mayo score, which 
was described by Schroeder et al. in 1987 (49, 50) (Table III). When the 
endoscopic part of the Mayo score is excluded, the index is referred to as the 
partial Mayo score. In the partial Mayo score, a therapeutic response is 
calculated as a decrease of t3 points and clinical remission as an absolute point of 
<2.5 (50). 
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Table II. Disease Activity Index 
Stool frequency Normal 0 
 1-2 stools/day more than normal 1 
 3-4 stools/day more than normal 2 
 >4 stools/day more than normal 3 
Rectal bleeding None 0 
 Streaks of blood 1 
 Obvious blood 2 
 Mostly blood 3 
Mucosal appearance Normal 0 
 Mild friability 1 
 Moderate friability 2 
 Exudation, spontaneous bleeding 3 
Physician’s rate of disease 
activity 
Normal 0 
 Mild 1 
 Moderate 2 
 Severe 3 
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Table III. Mayo Score 
Number of stools Normal 0 
 1-2 stools/day more than normal 1 
 3-4 stools/day more than normal 2 
 >5 stools/day more than normal 3 
Rectal bleeding None 0 
 Visible blood with stool less than 
half the time 
1 
 Visible blood with stool more than 
half the time 
2 
 Passing blood alone 3 
Mucosal appearing at 
endoscopy 
Normal or inactive disease 0 
 Mild disease 1 
 Moderate disease 2 
 Severe disease 3 
Physician’s rating of disease 
activity 
Normal 0 
 Mild 1 
 Moderate 2 
 Severe 3 
 
 
1.4 QUALITY OF LIFE 
The Short Health Scale (SHS) was developed by Hjortswang et al. as a tool to 
evaluate the subjective quality of life in IBD patients (51, 52). SHS comprises a 
four-dimension questionnaire including symptom-burden, social function, 
disease-related worry and general well-being (Table IV). 
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Table IV. Short Health Scale 
How severe are the symptoms you suffer from your bowel disease? 
No symptoms  0 - - - - - - - - - - - - - -100 Very severe symptoms 
Do your bowel problems interfere with your activities in daily life? 
Not at all  0 - - - - - - - - - - - - - -100 Interfere to a very high degree 
How much worry does your bowel disease cause? 
No worry  0 - - - - - - - - - - - - - -100 Constant worry 
How is your general feeling of well-being? 
Very good  0 - - - - - - - - - - - - - -100 Dreadful 
 
1.5 MARKERS OF INFLAMMATION 
Clinical activity indices are valuable in disease assessment, but since they are 
partly subjective, the result might not reflect the true inflammatory activity 
efficiently enough. Endoscopy is time-consuming, expensive and unpleasant for 
the patient. Laboratory markers present an objective and minimally invasive way 
of measuring momentary inflammation and could thus facilitate discerning of 
risk patients. 
 
1.5.1 Circulating markers 
C-reactive protein (CRP) was first described in 1930 by Tillett and Francis (53). It 
is used as gold standard in evaluating inflammatory activity. CRP is an acute-
phase protein synthesized by hepatocytes as a response to inflammatory 
processes, infections and stress among others. Under normal circumstances CRP 
is produced in low quantities (<1 mg/L) (54). During inflammation, interleukin-6 
(IL-6), IL-1E and TNF influence the production of CRP, reaching levels of 50-
500 mg/L depending on the severity of inflammation (55). The half-life of CRP is 
short (19 h), resulting in a rapid decrease once the inflammation has ceased. It 
has shown to predict relapse in IBD and colectomy in severe UC, as well as 
correlation with disease activity in both diagnoses, however stronger in CD (56, 
57). Prior to anti-TNF treatment onset, baseline CRP-levels >5 mg/L has shown 
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to be associated with a higher response frequency than patients with CRP <5 
mg/L (58), similar results were recently confirmed by Jürgens et al. (59). 
Anti-Saccharomyces cerevisiae antibodies (ASCA) was in 1988 shown by Main et al. 
to be present in high titres in CD patients (60). For this reason, they declared a 
theory of yeasts playing a possible role in CD etiology. Giaffer et al. found higher 
IgG-levels in patients with ileal CD and suggested this to reflect an increased 
intestinal permeability (61). ASCA in CD has shown to be stable over time and 
does not depend on disease activity or duration (62). Presence of ASCA has not 
shown to predict anti-TNF therapy outcome (63). ASCA is detected in 39-70% of 
CD patients and 20-25% in UC patients respectively, compared with 0-5% in 
healthy controls (60, 64, 65). 
Calprotectin (S100A8/A9) was described in 1980 by Fagerhol et al. (66). 
Neutrophils, monocytes and reactive macrophages derive calprotectin, a protein 
with bacteriostatic and fungistatic properties (67). It is involved in intracellular 
signal transduction and exerts regulatory inflammatory functions (68). In various 
inflammatory conditions, fecal calprotectin has shown to increase multifold and 
can be used in IBD diagnosis and monitoring of IBD therapy (69-73). 
Calprotectin in blood has shown to correlate with disease activity in 
inflammatory arthritides such as rheumatoid arthritis and reactive arthritis (74-
76). Serum calprotectin has also shown to be elevated in children with IBD 
compared to controls (77). 
In biological fluids, nitric oxide (NO) has a very short half-life and is rapidly 
oxidized to nitrite (NO2-) and nitrate (NO3-). Previously, those compounds have 
been considered as stable end-products of NO. However, recent research suggests 
a reverse pathway in which nitrite and nitrate are reduced back to NO, 
functioning as NO backup supply when the enzymatic pathway is insufficient or 
malfunctioning, e.g. during hypoxic conditions. In 1994, Lundberg et al. and 
Benjamin et al. demonstrated stomach NO generation from inorganic nitrite 
reduction (78, 79). Those were the first reports confirming a nitric oxide synthase 
(NOS)-independent source of NO. Moreover, Jansson et al. has shown that 
dietary nitrate protects against gastric ulcers derived from non-steroid anti-
inflammatory (NSAID) drugs in the rat (80). This protection is eliminated after 
addition of topical antibacterial mouthwash, hence, the bacteria in the oral cavity 
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seem to play an important role in gastric NO generation (81). Webb et al. showed 
in a study that ingestion of beetroot juice, which contains large amounts of 
nitrate, caused a lowering of blood pressure (82). 
Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of 
urokinase-type plasminogen activator receptor (uPAR) and was identified in 1991 
(83). uPAR is present at different types of immune cells including activated T-
lymphocytes and macrophages. SuPAR is found in blood, plasma, serum, urine 
and cerebrospinal fluid. It reflects an overall activation of unspecific systemic 
inflammation and has shown to be up-regulated in human immunodeficiency 
virus (HIV), malaria and sepsis (84-86). Moreover, suPAR levels have shown to 
be associated with increased risk of respiratory cancer (87). Previous studies have 
shown suPAR to strongly correlate with TNF and also with CRP (88, 89). 
SuPAR blood concentration has also shown to be a risk marker in the general 
population (90). Whether suPAR itself promotes pro-inflammatory response, or if 
it is a result of increased immune activation is yet to explore. 
Ghrelin is a peptide hormone, playing an important role in appetite regulation 
and energy metabolism (91). It has also shown to be involved in immune 
responses and inflammatory processes (92, 93). Serum ghrelin levels have been 
reported to be significantly higher in CD and UC patients with active disease 
compared with patients in remission or healthy controls (94, 95). Furthermore, 
serum ghrelin levels have shown to correlate with CRP in IBD patients (95). 
Sung et al. found plasma ghrelin to increase following infliximab infusion (96). 
As the name suggests, endothelin-1 is produced in vascular endothelial cells 
during physiological conditions, promoting vasoconstriction (97). Moreover, 
mono- and polymorphonuclear leucocytes in mucosa can produce endothelin. 
Boros et al. showed in a rat model that endothelin-1 causes leukocytes to slow 
down and adhere to the endothelium (98). Cui et al. found endothelin-1 to be a 
strong chemoattractant for human neutrophils and monocytes (99). A link 
between leukocyte chemoattraction, mast cell breakdown and endothelin-1 has 
been suggested in another study by Boros et al. (100). Murch et al. found increased 
endothelin-1- levels in intestinal tissue from CD and UC patients (101). This was 
confirmed by Kanazawa et al. who reported high plasma levels of endothelin in 
both CD and UC (102). 
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1.5.2 Fecal calprotectin 
Fecal calprotectin is a sensitive marker for IBD and can separate IBD from 
irritable bowel syndrome (IBS) (103). However, calprotectin is not disease-
specific and may rise in conditions such as colon cancer and non-steroidal anti-
inflammatory drug (NSAID)-induced inflammation (104-107). Calprotectin is 
stable in room temperature and resistant to proteolysis, which makes it a feasible 
marker in clinical routine (67). Strong correlations between calprotectin and 
histological and endoscopic findings have been confirmed in several studies (108-
111). 
 
1.5.3 Luminal nitric oxide 
Furchgott and Zawadzki described endothelium-derived relaxing factor (EDRF) 
in 1980 (112).  EDRF was later found to be NO (113, 114), which was awarded 
the Nobel prize in 1998. NO is involved in numerous mechanisms throughout 
the body. First of all, it is a potent vasodilator, but has also important functions in 
e.g. platelet aggregation, mucus generation and leukocyte adhesion to the 
endothelium (115-118). Through its tiny size and lipophilic quality, NO can 
diffuse freely across membranes. There are different NO-formation pathways in 
the body: the enzymatic and the enzyme-independent way. The former pathway 
is oxygen dependent; amino acid L-arginine reacts with oxygen via NOS, 
deriving NO and L-citrulline (119). During inflammation, the inducible NOS 
(iNOS, NOS2) produces high amounts of NO. The latter pathway acts as an NO 
buffer during hypoxia. Organic nitrite and nitrate can via chemical reduction 
generate NO also under conditions with low oxygen availability. Depending on 
duration and anatomic site for the NO production, the effect can be both anti-
inflammatory and cytotoxic. Nitrite-derived NO stimulates mucosal blood flow 
and mucus production and decreases leakage across the epithelium, hence plays a 
significant role in host defence (120, 121). Herulf et al. showed an increase of 
luminal NO in IBD patients, which was later confirmed also in infective 
gastroenteritis, coeliac disease and collagenous colitis (122-125). 
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2 AIMS OF THE PRESENT THESIS 
The general aim of this thesis was to study markers of inflammation during 
pharmacological therapy of inflammatory bowel disease and acute colitis. 
Specific aims: 
x To study the long-term outcome concerning blood status and systemic 
inflammatory parameters, clinical activity index and quality of life in 
patients treated with infliximab 
x To evaluate the short- and long-term outcome in systemic inflammatory 
markers along with clinical activity in patients undergoing the first year of 
scheduled infliximab therapy 
x To study the temporary levels of fecal calprotectin and plasma-CRP along 
with clinical activity and clinical outcome during infliximab induction 
therapy 
x To evaluate luminal nitric oxide and plasma-CRP levels in association 
with response and colectomy rate in patients with acute colitis treated 
with glucocorticosteroids. 
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3 MATERIAL & METHODS, STUDY I-IV 
3.1 STUDY SUBJECTS 
Permission to perform the studies was obtained from the regional ethics 
committee and all subjects gave their informed consent prior to entering the 
study. Diagnosis of the patients with IBD (154 with CD and 8 with UC) included 
in paper I-III was based on clinical, endoscopic and histological criteria (Table 
V). The patients in paper IV (n = 45) were diagnosed with acute colitis based on 
clinical and endoscopic criteria. Paper II includes ten healthy volunteers. 
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Table V. Patients included in the thesis 
 Paper I Paper II Paper III Paper IV 
CD 103 22 29 N/A 
   Colon 75 15 20 - 
   Ileo-colonic 4 5 8 - 
   Small-     
intestine 
24 1 - - 
   Colon and  
upper GI-tract 
- 1 1 - 
Fistulae 24 N/A 8 N/A 
UC - - 8 N/A 
   Left-sided - - 2 - 
   Extensive - - 6 - 
Acute colitis - - - 45 
Abbreviations: CD = Crohn’s disease, UC = ulcerative colitis, GI = 
gastrointestinal, N/A = Not applicable. The numbers represent number of 
individuals. 
 
3.2 LABORATORY METHODS 
3.2.1 Blood samples 
Blood samples were drawn and centrifuged at 4ºC for 10 minutes at 3000 rpm. 
Plasma and serum was collected and stored at -70ºC until analysis. All analyses 
were carried out in duplicate and according to the manufacturers’ instructions. 
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3.2.2 Sampling of rectal NO 
The silicone Argyle™ catheter (Sherwood Medical, Tullamore, Ireland) was used 
to sample rectal NO (paper IV). Using lubrication gel, the catheter tip was 
positioned 10 cm above the anal sphincter. Ten mL of ambient air in a syringe 
was used to inflate the balloon. The air was left for 10 minutes to equilibrate with 
the luminal gas (126). Thereafter, the gas was withdrawn from the balloon, 
diluted to a final volume of 50 mL and analyzed with correction for dilution. 
Analyses were made within 10 minutes of sampling. 
 
3.2.3 Chemiluminescence 
Nitrite (paper I) was analyzed by reductive cleavage and subsequent 
determination of NO released into the gas phase by chemiluminescence. Plasma 
samples were introduced into a reducing solution (45 mmol potassium iodide and 
10 mmol iodine per litre in acetic acid) via a gas-tight syringe. The reduction 
chamber was kept at 60ºC controlled by a flow of warm water. The reducing 
solution was constantly bubbled with nitrogen, used as carrier gas for NO. An 
acid trap (sodium hydroxide 1M, 0º C) caught traces of acid before the NO gas 
was analyzed in the chemiluminescence system (Aerocrine AB, Stockholm, 
Sweden) (127). 
Measurements of luminal NO (paper IV) were made employing a CLD 700 
(EcoPhysics, Dürnten, Switzerland). In this instrument, gaseous NO reacts with 
an excess of ozone (O3) to form NO2, which when it turns from its excited state 
(NO2*) to its ground state releases excess energy as photons and emitted light. 
The light can be quantified via a photo-sensitive surface and amplified in a 
photomultiplier. The light production is directly proportional to the amount of 
NO, linear within the interval 1-100 000 parts per billion (ppb). 
 
3.2.4 Determination of IgA and IgG-ASCA 
ASCA (paper I) was analyzed with an in-house method. Fifty gram of 
Saccharomyces cerevisiae, baker’s yeast (Svenska Jästfabriken AB, Rotebro, 
Sweden), was heat-killed, pooled at a concentration of 108 particles/mL and 
stored at -20º C. After thawing, the yeast particles were resolved in 1 mL 0.9% 
NaCl, counted in a Bürker chamber and re-suspended to a final concentration of 
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106 particles/mL. Ten L human serum albumin (200 mg/mL, Pharmacia, 
Uppsala, Sweden) was added per mL yeast particles to avoid unspecific binding. 
Serum from healthy blood donors (group AB+) was used as background control.  
Sixty L of the Saccharomyces cerevisiae solution was mixed with 20 L  serum 
(patient or control) and incubated in room temperature for 30 min. Antibody-
antigen reaction was completed by adding 100 L of secondary antibody 
fluorescein isothiocyanate (FITC)-labelled rabbit anti-human IgG and IgA 
(DAKO A/S, Glostrup, Denmark) in 4º C phosphate buffer, incubated for 30 
min, washed and centrifuged. After decanting, the pellets were dissolved in 0.5 
mL phosphate buffer and analyzed in an EPICS XL-MCL flow-cytometer 
(Beckman Coulter Inc., Fullerton, CA, USA). 
 
3.2.5 Near infrared particle immunoassay 
High-sensitive CRP (paper II) was analyzed with high-sensitive near infrared 
immunoassay rate (NIPA rate) and turbidimetry by a UniCel DxC 800 (Beckman 
Coulter Inc., Fullerton, CA, USA). The principle is that an anti-CRP antibody-
coated particle binds to CRP in the presence of patient sample, forming an 
insoluble aggregate. This non-soluble aggregate makes the solution murky, 
resulting in an increased turbidity. The absorbance is measured at 940 nm and is 
proportional to the concentration of CRP (interval 0.2-380 mg/L). 
 
3.2.6 Enzyme-linked immunosorbent assay 
Serum calprotectin and suPAR (paper II) were analyzed with enzyme-linked 
immunosorbent assay (ELISA) (PhiCal® MRP 8/14 ELISA, Immundiagnostik, 
Bensheim, Germany, and suPARnostic® Standard Kit, Virogates, Birkerød, 
Denmark). This assay utilizes a “sandwich” technique with two monoclonal 
antibodies binding to the agent. The microplate is covered with antibodies which 
during the first incubation step bind to the added sample agent. In the next 
incubation step, a second antibody is added followed by a chromogenic substrate. 
During the last step, colour is developing proportional to the amount of agent in 
the sample. The reaction is terminated by adding acid to the wells and the 
absorbance is measured in a plate reader (NanoQuant infinite200, Tecan, Tecan 
Austria Gmbh, Salzburg, Austria). The absorbance for both calprotectin and 
suPAR was read at 450 nm against 620 and 650 nm respectively, as reference. 
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3.2.7 Radioimmunoassay 
Plasma ghrelin and endothelin (paper II) were analyzed with radioimmunoassay 
(RIA) (128). Ghrelin was analyzed with Ghrelin Total RIA Kit (Linco Research, 
St Charles, MO, USA) and endothelin by Euria-Endothelin, RB 304 (Euro-
Diagnostica AB Malmö, Sweden). In RIA, a fixed concentration of labelled 
tracer antigen is incubated with a constant dilution of antiserum. When 
unlabelled antigen is added to the system, there is competition between labelled 
tracer and unlabeled antigen for the number of binding sites on the antibody. 
Both methods utilize 125I to label the tracer. The amount of tracer bound to 
antibody will decrease as the amount of unlabelled antigen increases. 
 
3.2.8 Griess reaction 
Total nitrite in serum (paper II) was analyzed with the Griess reaction 
(Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemical Co., Ann Arbor, MI, 
USA) (129). This analysis is carried out in a two-step process. In the first step, 
nitrate (NO3-) is converted to nitrite (NO2-) utilizing nitrate reductase. In the 
second step, Griess-reagents are added to form a purple azo-compound. The 
colour is proportional to the amount of nitrite in the sample and measurement of 
the absorbance at 540 nm is used to determine the total nitrite concentration 
(NanoQuant infinite200, Tecan, Tecan Austria Gmbh, Salzburg, Austria). 
 
 
3.3 STATISTICS 
GraphPad Prism 5.0 (GraphPad, La Jolla, CA, USA) was used for statistical 
analyses (paper I-IV). In paper II, statistical analyses were also carried out with 
Stata 11.0 (StataCorp LP, College Station, TX, USA). Values are presented as 
mean ± SEM when data showed normal distribution. If data did not pass normal 
distribution test (employing Kolmogorov-Smirnov test), they are presented as 
median and interquartile range (IQR). P<0.05 was considered statistically 
significant. 
In paper I, the evaluation of test results before and after infliximab infusion was 
carried out with Student’s t-test or Wilcoxon matched-pair test. Trends over time 
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were analyzed with unmatched Student’s t-test employing Welch’s correction. 
Correlation was analyzed by linear regression. 
In paper II, results were calculated by Wilcoxon test for paired groups and Mann-
Whitney test for unpaired data. Correlations were tested utilizing Spearman 
nonparametric correlation. 
In paper III and IV, sensitivity and specificity were analyzed by receiver 
operating characteristic (ROC) curve. Survival curves were analyzed with 
Kaplan-Meier analysis along with log-rank test. Spearman nonparametric test 
served for correlation analyses. 

 
 
  
  20 
4 RESULTS 
4.1 PAPER I 
A total of 103 CD patients were monitored and were given altogether 1061 
infusions. Seventy-nine patients had inflammation located in the ileo-cecal or 
colonic mucosa, 24 patients had fistulizing disease. Of those, 92 patients (89%) 
responded to infliximab therapy and received a median of seven infusions during 
a period of up to five years. Infliximab was withdrawn in the 11 non-responders. 
In the initial responding group, 39 patients (42%) terminated infliximab therapy 
due to loss of response (n=11), side-effects (n=12) or other reasons (n=16). Mild 
circulatory side-effects could in most cases be handled by slowing the infusion 
rate or by treatment with corticosteroids or antihistamine. However, 12 patients 
experienced side-effects of such severe nature that infliximab had to be 
withdrawn.  
 
 
4.1.1 Clinical response and quality of life 
Clinical response according to the HBi decreased over the first year from 7.7 to 
5.5 (p<0.0001) and remained steady over the following four years. 
The four dimension-based visual analogue scale Short Health Scale (SHS) 
showed that quality of life improved significantly in each dimension with 
infliximab infusions, most markedly in the symptom burden-related question. 
 
4.1.2 Blood chemistry 
Hemoglobin and albumin increased with infliximab infusions, and platelets and 
leukocytes improved over time. CRP decreased with treatment and remained low 
the following years. There were no signs of renal affection evaluated as creatinine 
levels. 
 
Nitrite and ASCA were analyzed in subgroups. Nitrite levels tended to increase 
after infliximab infusions, from 74.8-125.3 nmol/L (p<0.001) over the first year. 
No relationships were found between ASCA and infliximab therapy. 
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4.1.3 Correlations 
A weak but significant correlation was found between HBi and CRP delta values 
(r=0.27, p<0.001). No correlations were found between HBi and other blood 
chemistry components. 
 
4.1.4 Summary and conclusions 
The enhanced blood chemistry values mirrors an overall improvement in patients 
responding to infliximab. The acute inflammation was rapidly suppressed as 
shown by CRP. Hemoglobin, albumin, platelets and leukocyte levels were 
stabilized over time, along with positive results in clinical activity index and 
quality of life. These results confirm infliximab to be effective in both short- and 
long-term outcome in patients with moderate to severe CD. 
Stenosis and fistula development are common in the progressive course of CD, 
and an HBi normalization (<5 points) should be a hard goal in the evaluation of 
infliximab therapy outcome. A prompt symptomatic relief was shown already 
within one week. 
In the search of a correlation between clinical activity and biomarkers, we found 
CRP to be the most reliable one, however only weakly associated with patients’ 
symptoms evaluated as HBi. 
 
4.2 PAPER II 
Paper II included 22 CD patients undergoing the first year of scheduled 
infliximab therapy. Fifteen patients had disease located to the colon, five patients 
in the ileum and colon, one patient in colon and upper gastrointestinal tract and 
one patient in ileum only. Seven patients were anti-TNF-naïve at the study start 
and 15 patients had received a maximum of five previous infusions. Blood 
samples were drawn prior to infliximab infusion and at follow-up visit one week 
later. This routine was repeated after six months (three to four infusions later). 
Ten healthy volunteers served as controls. 
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4.2.1 Clinical activity 
Out of 22 paired observations, 15 (68%) had a clinical response or reached 
clinical remission at the first post-infusion visit. HBi decreased from 8.3 (5.0-11.3) 
to 4.5 (3.4-7.3) (p<0.01). At the second pre-infusion visit, HBi levels had returned 
to baseline levels, but improved in all patients but one at the second post-infusion 
visit, from 7.0 (4.0-13.1) to 5.3 (2.9-7.8) (p<0.001). 
 
4.2.2 Blood chemistry markers 
Hs-CRP showed a great variability in concentrations and was separated from 
healthy controls solely at the 6-month pre-infusion visit. It did however decrease 
with infliximab, but significantly only at the second post-infusion visit. 
Calprotectin in serum decreased with infliximab infusions at both follow-up 
occasions but did not reach normal levels, hence were separated from healthy 
controls at all four study visits. Total nitrite tended to increase with infliximab 
infusions and was separated from healthy controls throughout the study. SuPAR 
levels did not change with infliximab infusions, but instead indicated a constant 
activation of the inflammatory response being elevated at each study visit as 
compared with controls. Ghrelin decreased with infliximab infusions (significant 
at the first post-infusion visit), but did not differ from controls at any study visit. 
Endothelin decreased with infusions, significantly at the 6-month follow-up. The 
pre-infusion levels were similar to those of controls, but lower after infusions. 
 
4.2.3 Correlations 
A correlation was found between HBi and hs-CRP (Spearman r=0.32, p<0.05). 
None of the other markers correlated with activity index. However, hs-CRP 
correlated with serum calprotectin (Spearman r=0.35, p<0.05) as well as with 
suPAR (Spearman r=0.33, p<0.05). 
 
4.2.4 Summary and conclusions 
Serological inflammatory markers were studied as an attempt to monitor disease 
activity in a minimal invasive manner. The correlation between HBi and hs-CRP 
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favours this marker for evaluation of anti-TNF therapy response. However, the 
great variability in hs-CRP concentrations as well as its non-IBD specificity 
makes it a less useful marker. 
Total nitrite represents total nitrate and nitrite levels. Nitrate is present in the 
blood stream in far higher amounts than nitrite and both compounds contribute 
to NO generation. Nitrite-derived NO is suggested to act cytoprotectively to 
myocardial ischemia (130). Attenuated ischemic conditions and hence increased 
oxygen availability might theoretically be contributing to the increased nitrite 
concentrations in IBD patients following infliximab infusion. However, it does 
not explain the difference from healthy controls. 
Infliximab seems to decrease inflammatory activity promptly with obvious 
improvement one week after infusion. However, it does not normalize 
inflammatory markers over long-term scheduled therapy, illustrated by the 6-
month infusion visit concentrations which were similar to baseline levels. Also, 
the constantly increased levels of calprotectin, nitrite and suPAR compared with 
healthy controls indicate an ongoing subclinical inflammatory activity. 
There were no differences in inflammatory markers or activity index between 
anti-TNF naïve patients and those who had received previous infusions prior to 
study start. 
 
4.3 PAPER III 
Fecal calprotectin and CRP along with clinical activity were evaluated in 37 IBD 
patients (29 with CD and 8 with UC) during infliximab induction therapy 
(infusions week 0, 2 and 6). Of the CD patients, 20 had colonic disease, 8 had 
ileocolonic disease and one had disease located in the colon and stomach. Eight 
patients had concurrent fistulizing disease. Of the UC patients, six had extensive 
colitis and two had left-sided colitis. Twenty hospitalized patients received 
infliximab due to acute exacerbation and 17 as elective out-patient induction 
therapy. At baseline, six patients had mild to moderate endoscopic inflammation 
and 31 moderate to severe. Eleven patients had azathioprine and corticosteroids, 
four had azathioprine monotherapy, 14 patients had corticosteroid monotherapy 
and eight had no IBD-related pharmacological treatment. 
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4.3.1 Clinical activity 
Based on the HBi and partial Mayo score, 31 patients (84%) responded to 
infliximab and 24 (65%) reached clinical remission after induction therapy. Six 
patients (3 CD, 3 UC) did not respond. 
 
4.3.2 Fecal calprotectin and CRP 
At baseline, the median fecal calprotectin level in the total group was 2060 (1495-
5507) g/g and CRP 13 (6.5-35.5) mg/L. In the responding group median 
calprotectin was 210 (70-358) g/g after induction therapy compared with non-
responders with a median value of 1405 (304-2171) g/g. The CRP-levels in the 
same groups were 2 (1-4) and 5.5 (3.5-27.5) mg/L, respectively.  
 
4.3.3 Predictive values 
The fecal calprotectin ROC analysis best cut-off point was 221 g/g (sensitivity 
80%, specificity 67%), with an area under the curve computed to 0.81. Kaplan-
Meier analysis of responders showed that an FC level exceeding 221 g/g after 
induction therapy was associated with an incident (need for surgery, shortening 
of infusion interval from every eight to every six weeks, dosage increase from 5 
mg/kg to 10 mg/kg bodyweight) within 24 weeks after induction therapy 
(p<0.05). In patients with calprotectin <221 g/g, two out of 16 (13%) had an 
incident within 24 weeks. Among those with calprotectin >221 g/g the 
corresponding number was 8 out of 15 (53%) within the same period. 
The CRP ROC analysis best cut-off point was 2.5 mg/L (sensitivity 70%, 
specificity 76%, area under the curve 0.78). The Kaplan-Meier curve showed that 
a CRP>2.5 mg/L after induction therapy was associated with an incident within 
24 weeks (p<0.05). In patients with CRP levels below 2.5 mg/L, three out of 19 
(16%) had an incident within 24 weeks. In patients with CRP levels exceeding 2.5 
mg/L the corresponding number was 7 out of 12 (58%). 
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4.3.4 Concomitant azathioprine treatment 
When comparing patients who were concomitantly treated with azathioprine 
with those who were not, we found significantly higher CRP levels after 
induction therapy in patients without azathioprine with median values of 4 (2-
7.5) mg/L compared to 1 (1-3) mg/L in patients with combined therapy 
(p<0.05). None of the non-responders were concomitantly treated with 
azathioprine. 
 
4.3.5 Correlations 
When combining pre- and post-infusion data, clinical disease activity correlated 
with fecal calprotectin (Spearman r=0.62, p<0.0001) as well as with CRP 
(Spearman r=0.60, p<0.0001). Furthermore, calprotectin correlated with CRP 
(Spearman r=0.59, p<0.0001). 
 
4.3.6 Summary and conclusions 
The study shows that clinical indices correlate well with fecal calprotectin and 
CRP during infliximab induction therapy at week 0, 2 and 6, and furthermore, 
that a calprotectin level exceeding 221 g/g after induction therapy is associated 
with an incident within the following 24 weeks. In patients responding to 
infliximab, the clinical indices, fecal calprotectin and CRP decreased significantly 
from baseline at 12 weeks. 
In this study, CRP showed no capability in predicting flare-up. The best cut-off 
point (2.5 mg/L) lies within the normal interval (<3 mg/L). CRP levels remained 
slightly increased in patients without concomitant azathioprine therapy. A 
similar result has been reported by Sokol et al (131). None of the non-responders 
were concomitantly treated with azathioprine. These results support the notion 
that combination therapy of azathioprine and infliximab is superior to 
monotherapy (39). 
Only four patients had calprotectin levels below 50 g/g after induction therapy, 
even though 25 reached clinical remission. Patients responding to treatment with 
sustained elevated fecal calprotectin levels should be closely monitored since 
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there is an increased risk of flare-up. Patients in clinical remission along with 
calprotectin levels <221 g/g are at low risk. 
 
4.4 PAPER IV 
Luminal nitric oxide was analyzed in 45 patients hospitalized due to acute colitis 
and treated with corticosteroids as first-line therapy to subdue the inflammation. 
NO was measured before GCS onset and on the third day of treatment. Some of 
the patients had established IBD diagnoses (CD or UC) whereas others were 
naïve with no specific diagnosis other than acute colitis. CRP was analyzed as a 
comparative marker for acute inflammation.  
 
4.4.1 Clinical activity 
Response to therapy was evaluated as a decrease of  3 points in disease activity 
index (DAI, UC) or HBi (CD). In patients with no yet established sub-diagnosis, 
the HBi was used. 
Baseline activity index in the total group was 10 (8-11), which decreased to 7 
(4.5-9.5) on day 3 after GCS onset. When grouping patients due to surgical 
outcome, activity index over the first 3 days decreased significantly in patients 
spared from colectomy, from 10 (8-11) to 7 (4-8.5) (p<0.001). The corresponding 
values in colectomized patients did not differ over time [11.5 (9-12) to 11 (7.5-
13.5)]. 
 
4.4.2 NO and CRP 
In patients responding to GCS (n = 17, 38%), baseline median NO level was 
14444 (3200-24074) ppb and did not change significantly at day 3 [11833 (1306-
30950) ppb]. In the non-responding group of patients, the corresponding levels 
were 1675 (313-5109) ppb and 1111 (483-3996) ppb, respectively. The non-
responders had significantly lower NO-levels at both baseline and day 3 (p<0.05). 
Out of 28 non-responders, seven received azathioprine, seven started infliximab 
therapy and 14 underwent colectomy.  
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When comparing NO-levels in patients who were colectomized (n=14) within 
one month from hospitalization with those who were not (n=31), significantly 
lower levels were found in colectomized patients at both baseline and day 3 
compared with responders (p<0.01). In patients spared from colectomy, baseline 
NO was 8450 (3167-15111) ppb, while in colectomized patients the level was 450 
(220-1663) ppb. The day 3 levels were 4800 (750-24400) ppb and 590 (300-1583), 
respectively. The levels did not change over time within the groups. 
Baseline CRP in the total group was 33 (7-41.5) mg/L. Responders and non-
responders did not differ in baseline levels; 29.5 (12-38.5) and 33 (7-52) mg/L, 
respectively. Colectomized patients had higher baseline CRP levels than those 
who eluded surgery; 40 (27-48) and 22 (7-38.5) mg/L respectively (p<0.05). 
 
4.4.3 Predictive values 
The best NO cut-off point to differentiate between GCS responders and non-
responders was 4772 ppb, with a sensitivity and specificity of 71% and 75%, 
respectively. 
When performing ROC-analysis on luminal NO as a predictor for colectomy, the 
best cut-off point was 2239 ppb, with a sensitivity and specificity of 86% and 
81%, respectively, and an area under the curve of 0.88. Kaplan-Meier analysis 
showed that a baseline NO level below 2239 ppb was significantly associated 
with colectomy within one month (p<0.0001). Twelve out of 18 (67%) in patients 
with baseline NO <2239 ppb were colectomized. The corresponding number in 
patients with baseline NO >2239 ppb was two out of 27 (7%). 
Studying the predictive value of CRP, ROC-analysis was not significant. 
 
4.4.4 Summary and conclusions 
This study shows that luminal nitric oxide does not change over the first three 
days of GCS therapy; hence, GCS does not seem to have an immediate effect on 
NO production. 
Patients with increased baseline NO levels seem to benefit from GCS therapy in a 
higher extent than do patients with lower baseline values, in response as well as 
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in colectomy rate. The low values in non-responders and colectomized patients 
may reflect an extended destruction of NO-producing mucosa due to severe 
inflammation.  
The clinical activity indices showed that 3 days seem to be enough to evaluate 
therapy response or failure. In patients with a poor response to GCS along with 
low luminal NO, rescue therapy measures are indicated. 
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5 GENERAL DISCUSSION 
To be diagnosed with a lifelong disease such as IBD may naturally result in 
worry and questions regarding disease progression, therapy options and outcome. 
Seeing that disease symptoms and severity vary widely within this patient group 
and flares most of the times are not possible to predict, many of these questions 
will be left unanswered (132). Available pharmacological therapy is symptom 
alleviating, not curing. Many patients will develop steroid dependency or 
resistance over years, requiring therapy supplement according to the step-up 
regimen. Activity indices convey essential disease course information, but need to 
be complemented with objective inflammatory markers to evaluate the true 
inflammatory activity. Both systemic and local markers of inflammation 
contribute with important information of the situation. Systemic CRP has shown 
to correlate strongly with disease activity index in CD, whereas local fecal 
calprotectin correlates robustly with endoscopic indices. 
In this thesis, inflammatory markers have been studied at systemic level (paper I - 
IV) as well as locally in the gut (paper III and IV). The study shows that 
infliximab effectively ameliorates the IBD symptoms and that clinical response 
and quality of life improves within one week from infusion. Also, blood 
chemistry markers improve during this period. However, inflammatory markers 
did not constantly follow the same trend, most clearly illustrated by calprotectin, 
nitrite and suPAR. Moreover, rectal NO did not change over the three-day 
follow-up during GCS therapy. Fecal calprotectin can be used as a predictor of 
flare-up during infliximab therapy, whereas luminal NO showed strong 
colectomy predicting capability during GCS therapy. 
In paper I, improvements in hemoglobin, albumin and CRP over short- and long-
term infliximab therapy were confirmed. In IBD patients, chronic inflammation 
or intestinal blood loss, together with malfunctioning duodenal iron absorption, 
cause a negative iron balance and anemia. One third of the IBD population has 
hemoglobin concentration below 120 g/L (the lower reference limits are 120 g/L 
in women and 130 g/L in men) (133). Hemoglobin is regularly monitored in IBD 
patients to assess the presence or absence of anemia, which it is the most 
common systemic complication in IBD and has a great impact of quality of life 
(134, 135). Serum albumin concentration has been shown to correlate with CRP-
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levels in UC patients (136). The improved circulating albumin levels following 
infliximab infusion reflect a decreased leakage of circulating albumin to 
intercellular space, i.e. less inflammation. The decrease in CRP-levels illustrates a 
prompt inhibition of the acute inflammation. CRP is still used as gold standard 
marker in evaluation of systemic inflammatory activity. It is cheap and rapid to 
analyse, but lacks disease specificity, making it unspecific to rely on solely. 
Albeit, CRP was the only marker correlating with activity index in paper I and II. 
This is in line with findings from other groups (57, 137). 
Inflammatory markers improved with infliximab infusions in paper II. However, 
the expected normalization over short- (one week) and long-term (six months) 
was absent and furthermore, markers tended to return to baseline level at the 
second pre-infusion visit. These results indicate either an insufficient time-to-
follow-up, or merely a persistent activation of inflammatory response unaffected 
by infliximab. This was illustrated especially by suPAR, calprotectin and nitrite 
being constantly separated from healthy controls. Paper II describes suPAR levels 
for the first time in inflammatory bowel disease. SuPAR has no diagnostic value, 
but has shown prognostic strength in several infectious diseases (85, 138, 139). 
SuPAR levels in CD patients were as expected considerably lower than for 
example in sepsis studies, but still significantly increased compared with healthy 
individuals. Moreover, suPAR did not change with infliximab infusions. The 
course of disease does not seem to change with infliximab therapy, managing 
only to decrease the short-term inflammation. Moreover, patients’ naïve to anti-
TNF therapy at study start showed no difference in outcome from previously 
treated patients after sub-analysis. A possible explanation might be that all anti-
TNF naïve patients were treated with other anti-inflammatory drugs (GCS, 
azathioprine) prior to infliximab onset, which probably already suppressed the 
inflammatory activity. The great variability in hs-CRP levels in paper II could be 
explained by the fact that a majority of the patients were, according to the step-up 
strategy, treated with GCS and/or immunosuppressants prior to infliximab onset. 
Neither endothelin nor ghrelin were suitable as markers of inflammation in this 
study. Ghrelin levels did not differ between patients and controls at any study 
visit, even though it tended to decrease with infliximab infusions. Ates et al. 
found higher serum ghrelin levels in IBD patients with active disease than 
patients in remission, but differences were not significant between the total group 
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of IBD patients and healthy controls (95). Thus, ghrelin may play a role in 
inflammation, but does not seem useful as marker of infliximab therapy 
evaluation. Endothelin-1 has been suggested to be involved in IBD inflammation 
(101). Furthermore, the non-selective endothelin-receptor antagonist bosentan 
has shown to ameliorate inflammation in animal models (140, 141). However, 
since a clear role of endothelin in IBD has not been confirmed, all forms of 
endothelin; endothelin-1, -2 and -3 were analyzed. Pre-infusion levels were 
similar to healthy control levels, whereas post-infusion levels were significantly 
lower. The results cannot be explained from an inflammatory perspective, but 
rather from general aspects such as age, physical activity or prandial status. 
A nitrite and total nitrite increase tendency with infliximab infusions was shown 
in two publications (paper I and II), employing two separate analysis methods. 
This favours the suggestion of nitrite and hence NO acting anti-inflammatory 
(142, 143). During inflammation, superoxide destroys NO to form peroxynitrite 
which can isomerize to form nitrate. With less superoxide and hence less nitrate 
derived, NO might instead form nitrite. Moreover, TNF up-regulates the 
endothelial arginase expression, which depletes NOS of L-arginine, leading to a 
decrease in NO production (144). Anti-TNF therapy might therefore give the 
opposite result, with increased NO and hence nitrite levels. An additional 
hypothesis is that the patients improve their plasma nitrite levels because of a 
richer dietary uptake of nitrite and nitrate once the inflammation is alleviated. 
Paper II and III showed that serum and fecal calprotectin do not decrease to 
levels of those in healthy controls with infliximab therapy, irrespectively of 
systemic or local analysis. Calprotectin was described in 1980 and has rapidly 
been implemented as a fecal marker of inflammation in clinical routine, as it 
closely reflects the granulocyte migration through the gut wall and hence 
inflammatory activity (145). In paper III, only four patients had levels below the 
reference limit after induction therapy even though 25 patients reached clinical 
remission according to disease activity indices. Evidently, clinical activity indices 
underestimate the inflammatory activity often found in patients with quiescent 
disease (146). 
In paper III, fecal calprotectin was found to decrease significantly in responders 
following infliximab induction therapy and moreover, to be a predictor of 
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incidents as signs of flare-up the following 24 weeks. This is in line with previous 
findings by Garcia-Sanchez et al. who found that CD and UC patients with 
calprotectin exceeding 200 respectively 120 g/g relapsed 4 respectively 6 times 
more often than patients with lower values (71). Gisbert et al. found a significant 
risk for relapse at a cut-off level of >150 g/g in IBD patients in stable remission 
(147). Similar findings have also been reported in pediatric IBD populations 
(148).  
In paper IV, NO levels in acute colitis patients undergoing GCS therapy were 
shown to differ between responders and non-responders. However, NO levels did 
not decrease over the first three days of therapy, indicating that NO seems either 
not to be affected by GCS, or the change is delayed and occurs after a prolonged 
period (149). Since NO levels remain at baseline level after three days of therapy, 
baseline level is sufficient to predict outcome. Patients with increased NO seem 
to benefit more from GCS therapy. It is not obvious why patients with higher NO 
levels (reflecting increased inflammatory activity) would respond better to GCS. 
The results can be compared to those from Louis et al., who found patients with 
CRP>5 mg/L to respond better to therapy than those with lower levels (58). In 
paper III, patients with the most severe endoscopic inflammation had lower fecal 
calprotectin values than patients with moderate endoscopic inflammation, 
possibly caused by an increased mucosal secretion. This theory might also be 
applied in rectal NO and acute colitis, where a damaged epithelium could result 
in reduced NO production. In the same way as fecal calprotectin, luminal NO 
measures inflammation close to the inflamed area and should thus give a better 
estimate of the inflammatory activity. Lundberg et al. showed in 1994 that NO 
values were higher in samples obtained close to lesions than farther away from 
inflamed area in UC (150). 
In all four studies, only weak correlations between clinical activity index and 
inflammatory markers were found. Not surprisingly, the strongest correlation was 
found between fecal calprotectin and clinical activity index (paper III). Fecal 
calprotectin has an advantage of measuring inflammation on site. Elevated CRP 
levels are strongly correlated with CD, whereas in UC, CRP increase is only 
moderate or absent (151). This might have contributed to the variation in CRP 
concentrations in paper III and IV, since both CD and UC patients were 
included.  
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The activity indices’ underestimation of the actual inflammatory activity may not 
be of importance in evaluating therapy outcome since it for example efficiently 
separates responders from non-responders. However, biological therapy is very 
expensive, and when the patient has reached stable clinical remission, the 
question of anti-TNF-withdrawal might be raised. One must on that occasion 
bear in mind that a subclinical inflammation most likely is present and hence, 
withdrawal might elicit a rapid flare-up, with less chance of regained anti-TNF 
response due to development of antibodies to infliximab (152, 153). 
From the patients’ point of view, increased wellbeing, quality of life and 
decreased symptom burden are probably the primary goals. However, due to the 
risks brought by long-term continuous inflammation, it is of most importance to 
eliminate as much as possible of inflammatory activity. A combination of clinical 
activity index and eligible inflammatory markers, chiefly circulating CRP, 
calprotectin, nitrite and suPAR, fecal calprotectin and luminal NO, can form 
strong tools in clinical practise and evaluation of medical therapy. 
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6 CONCLUSIONS 
Biological therapy with infliximab brings rapid improvement in clinical activity, 
quality of life and blood chemistry. The improvement maintains over years. 
Systemic calprotectin, nitrite and suPAR are valuable markers in evaluation of 
inflammatory activity during the first year of infliximab therapy, whereas ghrelin 
and endothelin showed weaker results. SuPAR was shown for the first time in 
inflammatory bowel disease to be constantly elevated in CD patients treated with 
infliximab, compared with healthy controls. 
Clinical activity index correlates with fecal calprotectin and CRP during 
infliximab induction therapy. Fecal calprotectin can be used as a predictor of 
flare-up following infliximab induction therapy, being superior to CRP in this 
aspect. In mild to moderate IBD, fecal calprotectin correlates with baseline 
endoscopic index. In more severe disease, this correlation is lost. Infliximab 
therapy combined with azathioprine seems beneficial as evaluated by CRP. 
Baseline luminal nitric oxide can be used as a predictor of colectomy in acute 
colitis patients treated with GCS. Patients with low baseline NO and poor 
response to GCS should be given rescue therapy in order to prevent colectomy. 
Patients who underwent colectomy had higher baseline CRP and lower NO 
concentration compared with patients spared from surgery. 
Among the systemic inflammatory markers, hs-CRP showed the most useful 
properties due to its association with clinical activity index. Of the local 
inflammatory markers, fecal calprotectin and luminal NO were very useful in 
terms of relapse and surgery. 
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7 SUMMARY IN SWEDISH 
Inflammatorisk tarmsjukdom är ett samlingsnamn för diagnoserna Crohn’s 
sjukdom och ulcerös colit. Dessa sjukdomar är kroniskt återkommande med skov 
som ger svåra symtom (blod- eller slemtillblandade diarréer, smärta, 
viktnedgång). Crohn’s sjukdom kan drabba hela mag-tarmkanalen från mun till 
anus och kan även medföra fistelproblematik och förträngningar i tarmen. 
Ulcerös colit drabbar tjocktarmen med kontinuerlig inflammation. Båda 
patientgrupperna löper en avsevärt högre risk än normalbefolkningen att drabbas 
av colorektalcancer. Tillgänglig behandling syftar till att inducera och bevara 
symtomfrihet. Tillförlitliga markörer skulle kunna underlätta utvärdering av 
behandlingssvar och inflammatorisk aktivitet på ett objektivt sätt. Vi ville med det 
här projektet studera olika markörer i blod, avföring samt rektalgas vid samtidig 
behandling av inflammatorisk tarmsjukdom för att se hur de förändras under 
behandling samt om de stämmer överens med de index som används för att 
uppskatta sjukdomsaktivitet. 
I det första arbetet följde vi Crohn-patienter före och efter infliximabinfusion 
under första behandlingsåret och därefter årligen i upp till fem år. Vi visade att 
ämnen i blod som påverkas av inflammation normaliserades med behandling och 
att behandlingseffekten kvarstod över lång tid. Patienterna rapporterade en ökad 
livskvalitet i och med behandling. 
I arbete två analyserade vi sex inflammationsmarkörer i plasma och serum före 
och efter infliximabinfusion hos Crohn-patienter under deras första behandlingsår 
med infliximab. Som jämförelse analyserade vi även samma markörer hos friska 
kontroller. Resultaten visade att inflammationen minskade med behandling, men 
flera av markörerna var fortfarande konstant förhöjda jämfört med friska 
kontroller, vilket indikerar en ständigt pågående subklinisk inflammation. 
I arbete tre följde vi fekalt calprotectin och plasma-CRP hos patienter med 
Crohn’s sjukdom och ulcerös colit under induktionsbehandling med infliximab. 
Hos patienter som svarade på behandling sjönk calprotectin och CRP samtidigt 
som aktivitetsindex förbättrades. Calprotectin kunde även användas för att 
prediktera nytt skov inom följande 24 veckor. 
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I det fjärde arbetet mätte vi NO i rektalgas före och tre dagar efter påbörjad 
kortikosteroidbehandling hos patienter som sjukhusvårdades för skov av akut 
colit. Lyckas man inte häva inflammationen i tid kan patienten behöva genomgå 
colektomi (tjocktarmen opereras bort). De patienter som svarade på behandling 
hade vid bägge mättillfällena högre NO-värden än de som inte svarade. NO 
kunde även användas för att prediktera colektomiutfall inom en månad. 
Sammanfattningsvis har flera av markörerna i det här arbetet visat sig värdefulla i 
bedömningen av inflammatorisk aktivitet och skulle kunna utgöra ett viktigt 
verktyg i den kliniska vardagen. 
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